Biagio Didona, MD


Director
Rare Diseases Centre
Istituto Dermopatico dell Immacolata-Istituto di
Ricovero e Cura a Carattere Scientifico
(IDI-IRCCS)
Via Monti Creta, 104, 00167 Roma, Italy

Biography

EDUCATIONAL QUALIFICATIONS

• (1975) Degree in Medicine, graduated with honours, University of Rome La Sapienza, Rome, Italy
• (1978) Specialization in Dermatology and Venereology, University of Rome La Sapienza, Rome, Italy
• (1986) Specialization in Allergology, University of Rome La Sapienza, Rome, Italy

PROFESSIONAL EXPERIENCES

• (1979-2002) Assistant and Senior Assistant Dermatologist at First Dermatological Ward of the Istituto Dermopatico dellImmacolata – Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy
• (2002-2014) Head of First Dermatological Ward at the Istituto Dermopatico dellImmacolata, Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy
• (2014-Present) Director of Rare Diseases Centre, Istituto Dermopatico dell Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS

Research Interest

His research interest includes: Autoimmune bullous disorders, Genodermatosis, Vasculitis and Livedoid vasculopathy, lyell syndrome, Use off-label of etanercept and Dermatologic theraphy.

Scientific Activities

MEMBERSHIPS

• Member of ESDR
• Member of ADOI (Associazione Dermatologi Ospedalieri Italiani)
• Principal Investigator over ten international trials and studies

Publications

1. Didona D, Paolino G, Donati M, Caposeina D, Calvieri S, Didona B. Resolution of a case of pediatric pemphigus vulgaris treated with rituximab. Acta Dermatovenerol Croat. 2014; 22(4): 288-290.
2. Napolitano M, Annessi G, Didona D, Didona B. Multifocal melanoma in situ of the penis treated with topical Imiquimod. J Eur Acad Dermatol Venereol. 2014. doi:10.1111/jdv.12835
3. Paradisi A, Tabolli S, Didona B, Sobrino L, Russo N, Abeni D. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol. 2014; 71(6): 1110-1116. doi:10.1016/j.jaad.2014.07.050
4. Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014; 71(2): 278-283. doi:10.1016/j.jaad.2014.04.044
5. Napolitano M, Didona B, Passarelli F, Annessi G, Bono R. Amelanotic melanoma mimicking cutaneous epitheliomas. J Am Acad Dermatol. 2014; 70(4): e75-e76. doi:10.1016/j.jaad.2013.10.012
6. Calabresi V, Sinistro A, Cozzani E, et al. Sensitivity of different assays for the serological diagnosis of epidermolysis bullosa acquisita: analysis of a cohort of 24 Italian patients. J Eur Acad Dermatol Venereol. 2014; 28(4): 483-490. doi:10.1111/jdv.12129
7. Napolitano M, Giampetruzzi AR, Didona D, Papi M, Didona B. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. J Am Acad Dermatol. 2013; 69(6): e303-e305. doi:10.1016/j.jaad.2013.07.036
8. Vahlquist A, Blockhuys S, Steijlen P, et al. Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. Br J Dermatol. 2014; 170(1): 173-181. doi:10.1111/bjd.12626
9. Giampetruzzi AR, Mondino C, Facchiano A, et al. Association of dermoscopic profiles of telangiectases with nailfold videocapillaroscopic patterns in patients with systemic sclerosis. J Rheumatol. 2013; 40(9): 1630-1632. doi:10.3899/jrheum.130171.
10. Sampogna F, Camaioni DB, Giampetruzzi AR, et al. Chronic idiopathic acrocyanosis and methylenetetrahydrofolate reductase C677T (p.Ala222Val) and A1298C (p.Glu429Ala) polymorphisms. Eur J Dermatol. 2013; 23(3): 356-361. doi:10.1684/ejd.2013.2034
11. Terrinoni A, Serra V, Codispoti A, et al. Novel tranglutaminase 1 mutations in patients affected by lamellar icthyosis. Cell Death Dis. 2012; 3: e416 doi: 10.1038/cddis.2012.152
12. Di Zenzo G, Di Lullo G, Corti D, et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest. 2012; 122(10): 3781-3790. doi:10.1172/JCI64413
13. Paradisi A, Cianchini G, Lupi F, et al. Quality of life in patients with pemphigus receiving adjuvant therapy. Clin Exp Dermatol. 2012; 37(6): 626-630. doi:10.1111/j.1365-2230.2011.04282.x
14. Terrinoni A, Codispoti A, Serra V, et al. Connexin 26(GJB2) mutations as a cause of the KID syndrome with hearing loss Biochem Biophys Res Commun. 2010; 395(1): 25-30. doi:10.1016/j.bbrc.2010.03.098
15. Terrinoni A, Codispoti A, Serra V, et al. Connexin 26(GIB2) mutations, causing KID syndrome, are associated with cell death due to calcium gating deregulation. Biochem Biophys Res Commun. 2010; 394(4): 909-914. doi:10.1016/j.bbrc.2010.03.073
16. Garcovich s, Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010; 24(8): 881-884. doi:10.1111/j.1468-3083.2009.03511.x
17. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009; 36(3): 150-153. doi:10.1111/j.1346-8138.2009.00616.x.
18. Tabolli S, Alessandroni L, Didona B, et al. A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol. 2009; 34(3): 304-308. doi:10.1111/j.1365-2230.2008.02932.x
19. Paradisi A, Sampogna F, Di Pietro C, et al. Quality of- life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol. 2009; 80(2): 261-269. doi:10.1016/j.jaad.2008.09.014.
20. Castori M, Majore S, Romanelli F, Didona B, Grammatico P, Zambruno G. Association of segmental neurofibromatosis 1 and oculo-auricolo-vertebral spectrum in a 24-year-old female. Eur J Dermatol. 2008; 18(1): 22-25. doi:10.1684/ejd.2008.0305
21. Didona B, Codispoti a, Bertini E, et al. Novel and recurrent ALDH3A2 mutation in Italian patients with Sjogren-Larsson syndrome. J Hum Genet. 2007; 52(10): 865-870. doi:10.1007/s10038-007-0180-z
22. Cianchini G, Corona R, Frezzolini A, ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and review of the literature. Arch Dermatol. 2007; 143(8): 1033-1038. doi:10.1001/archderm.143.8.1033
23. Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, Raskovic D. Pemphigus foliaceous teated with etanercept. J Am Acad Dermatol. 2006; 55(6): 1107-1108. doi:10.1016/j.jaad.2006.08.041
24. Has C, Wessagowit V, Pascucci M, et al. Molecular basis of Kindler syndrome in Italy: novel and recurrent Alu/Alu recombination, splice site, nonsense, and framshift mutations in the KIND1 gene. J Invest Dermatol 2006; 126(8): 1776-1783. doi:10.1038/sj.jid.5700339
25. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol. 2004; 150(6): 1198-1201. doi:10.1111/j.1365-2133.2004.05993.x
26. Terron-Kwiatkowski A, Terrinoni A, Didona B, et al. Atypical epidermolytic palmoplantar keratoderma presentation associated with a mutation in the keratin 1 gene. Br J Dermatol. 2004; 150(6): 1096-1103. doi:10.1111/j.1365-2133.2004.05967.x
27. D Errico M, Teson M, Calcagnile A, et al. Characterization of the ultraviolet B and X-ray response of primary cultured epidermal cells from patients with disseminated superficial actinic porokeratosis. Br J Dermatol. 2004; 150(1): 47-55. doi:10.1111/j.1365-2133.2004.05714.x
28. Ashton GH, McLean WH, South AP, et al. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. J Invest Dermatol. 2004; 122(1): 78-83. doi:10.1046/j.0022-202X.2003.22136.x
29. Posteraro P, Frances C, Didona B, Dorent R, Posteraro B, Fadda G. Persistent subcutaneous Scedosporium apiospermum infection. Eur J Dermatol. 2003; 13(6): 603-605.
30. Terrinoni A, Smith FJ, Didona B, et al. Novel and recurrent mutations in the genes encoding keratins K6a, K16 and K17 in 13 cases of pachyonychia congenita. J Invest Dermatol. 2001; 117(6): 1391-1396. doi:10.1046/j.0022-202x.2001.01565.x
31. Ruzzi L, Pas H, Posteraro P, et al. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol. 2001; 116(1): 182-187. doi:10.1046/j.1523-1747.2001.00229.x
32. Terrinoni A, Puddu P, Didona B, et al. A mutation in the V1 domain of K16 is responsible for unilateral palmoplantar verrucous nevus. J Invest Dermatol. 2000; 114(6): 1136-1140. doi:10.1046/j.1523-1747.2000.00983.x
33. DErrico M, Calcagnile A, Canzona F, et al. UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients. Oncogene. 2000; 19(3): 463-467.
34. Vernole P, Terrinoni A, Didona B, et al. An SRY-negative XX male with Huriez syndrome. Clin Genet. 2000; 57(1): 61-66. doi:10.1034/j.1399-0004.2000.570109.x
35. Papi M, Didona B. Unusual clinical presentations of vasculitis: what some clinical aspects can tell us about the pathogenesis. Clin Dermatol. 1999; 17(5): 559-564.
36. Papi M, De Pita O, Frezzolini A, Didona B. Prognostic factors in leukocytoclastic vasculitis: what is the role of antineutrophil cytoplasmic antibody? Arch Dermatol. 1999; 135(6): 714-715. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-6-dlt0699
37. Vernole P, Tullio A, Caporossi D, Didona B, Melino G, Tedeschi B. Bleomycin-induced chromosome aberrations in lymphocytes derived from patients with lamellar ichthyosis. Cancer Genet Cytogenet. 1999; 108(2): 154-157. doi:10.1016/S0165-4608(98)00136-8
38. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998; 134(4): 447-452. doi:10.1001/archderm.134.4.447
39. Pastore S, Corinti S, La Placa M, Didona B, Girolomoni G. Interferon-gamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. J Allergy Clin Immunol. 1998; 101(4 Pt 1): 538-544. doi:10.1016/S0091-6749(98)70361-6
40. Papi M, Didona B, Chinni LM, et al. Koebner phenomenon in an ANCA-positive patient with pyoderma gangrenosum. J Dermatol. 1997; 24(9): 583-586. doi:10.1111/j.1346-8138.1997.tb02297.x
41. Papi M, Didona B, De Pita O, Gantcheva M, Chinni LM. Chronic hepatitis C virus infection, mixed cryoglobulinaemia, leukocytoclastic vasculitis and antineutrophil cytoplasmic antibodies. Lupus. 1997; 6(9): 737-738. doi:10.1177/096120339700600911
42. Richard G, De Laurenzi V, Didona B, Bale SJ, Compton JG. Keratin 13 point mutation underlies the hereditary mucosal epithelial disorder white sponge nevus. Nat Genet. 1995; 11(4): 453-455. doi:10.1038/ng1295-453
43. Papi M, Didona B, Campana C, Simoni R, Cavalieri R. Unusual clinical presentation of cutaneous necrotizing vasculitis. Int Angiol. 1995; 14(2): 162-165.
44. Gobello T, Mazzanti C, Fileccia P, et al. X-linked dominant chondrodysplasia punctata (Happle syndrome) with uncommon symmetrical shortening of the tubular bones. Dermatology. 1995; 191(4): 323-327.
45. Papi M, Didona B, DePita O, et al. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol. 1993; 28(3): 485-486.
46. Stasi R, Cantonetti M, Abruzzese E, et al. Multiple skin tumors in long-term treatment with hydroxyurea. Eur J Haematol. 1992; 48(2): 121-122. doi:10.1111/j.1600-0609.1992.tb00580.x